No Data
No Data
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis With Cardiomyopathy
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Is Intellia Therapeutics Stock a Buy Now?
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
No Data